Brent L Saunders
CIK 1268854 · Chairman of the Board and CEO · last filed 2026-08-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AGN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
C/O SCHERING PLOUGH CORP
KENILWORTH, NJ 07033
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BLCO | Chairman of the Board and CEO | 974,158 | $17.66 | $17.20M | $1.01M | 14 | 2026-08-07 |
| SPRY | Director | 0 | $3.83 | $0 | -$1.71M | 6 | 2026-06-26 |
| SKIN | Director | 383,830 | $10.30 | $3.95M | $406.1K | 10 | 2025-06-18 |
| CSCO | Director | 24,143 | $111.58 | $2.69M | $0 | 7 | 2022-12-12 |
| BBIO | Director | 17,600 | $69.30 | $1.22M | $254.9K | 4 | 2022-06-24 |
| Allergan plc (AGN) Delisted | Chairman, President and CEO | 0 | — | — | $2.83M | 20 | 2020-05-11 |
| ACT | CEO and President | 131,862 | $48.13 | $6.35M | $0 | 2 | 2015-05-19 |
| Forest Laboratories, LLC (FRX) Delisted | CEO & President | 0 | $12.00 | $0 | $0 | 5 | 2014-07-02 |
| MRK | Senior Vice President | 50,783 | $141.97 | $7.21M | -$1.12M | 8 | 2009-11-04 |
Recent Filings · Page 7 of 8
79 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-10-05 | Allergan plc (AGN) Delisted | Tax (F) | −7,587 | -$2.14M | EDGAR |
| 2015-08-24 | Allergan plc (AGN) Delisted | Buy (P) | +1,000 | $301.9K | EDGAR |
| 2015-05-19 | ACT | Tax (F) | −3,449 | -$1.02M | EDGAR |
| 2015-03-31 | ACT | Grant (A) | +135,507 | $0 | EDGAR |
| 2014-11-14 | — | Tax (F) | −196 | -$43.5K | |
| 2014-07-03 | — | Grant (A) | +96,865 | $0 | |
| 2014-07-02 | Forest Laboratories, LLC (FRX) Delisted | Mixed | −255,299 | $0 | EDGAR |
| 2013-10-03 | Forest Laboratories, LLC (FRX) Delisted | Grant (A) | +209,109 | $5.00M | EDGAR |
| 2013-08-16 | Forest Laboratories, LLC (FRX) Delisted | Grant (A) | +1,761 | $0 | EDGAR |
| 2012-08-27 | Forest Laboratories, LLC (FRX) Delisted | Grant (A) | +2,172 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.